COVID-19: Vaccines and Therapeutics
The Pfizer-BioNTech COVID-19 vaccine was well tolerated and demonstrated 100% efficacy and robust antibody responses in a phase 3 clinical trial in 2,260 children aged 12-15, the vaccine鈥檚 makers announced.
As part of AHA鈥檚 Joining Hands for Greater Impact series, we talk to Atrium Health, American Airlines and Charlotte Douglas International Airport representatives about how they came together to 鈥済et shots in arms鈥 in Charlotte, N.C.
BREAKING NEWS related to vaccine effectiveness in children and the novel coronavirus pandemic that we wanted to share.
The Pfizer and Moderna COVID-19 vaccines reduced the risk of both asymptomatic and symptomatic SARS-CoV-2 infection by 90% at least two weeks after the second dose and by 80% at least two weeks after the first dose in a study of 3,950 vaccinated health care and other essential workers, the Centers鈥
AHA releases an infographic with storage requirements for the three FDA-authorized COVID-19 vaccines.
As more vaccine supplies become available and more jurisdictions expand priority categories or do away with them altogether, hospitals and health systems continue to work overtime to serve as access points.
Throughout the pandemic, innovative partnerships have helped hospitals and health systems ensure ongoing care for patients, health care workers and their communities.
AstraZeneca revised its data on its COVID-19 vaccine candidate, stating that its AZD1222 vaccine showed a 76% efficacy in preventing symptomatic COVID-19.
The White House announced a $10 billion investment in promoting public confidence in COVID-19 vaccines, particularly among the hardest-hit and highest-risk communities.
Throughout the pandemic, innovative partnerships have helped hospitals and health systems ensure ongoing care for patients, health care workers and their communities. Here are some of the success stories that have shone brightly at every phase of this public health emergency. Plus, there鈥檚 an鈥